EVALUATION OF QUALITY OF LIFE AND PSYCHOLOGICAL IMPLICATIONS IN PATIENTS WITH ROSACEA USING DERMATOLOGY LIFE QUALITY INDEX (DLQI) AND THE HOSPITAL ANXIETY AND DEPRESSION SCALE (HADS)

Author(s):  
Alpana Mohta ◽  
Asha Nyati ◽  
Aditi Agrawal ◽  
Suresh Kumar Jain ◽  
Ramesh Kumar Kushwaha ◽  
...  

Introduction: Rosacea is a chronic skin disease associated with high levels of psychological distress and a significant impact on quality of life. Objective: To evaluate the quality of life, depression and anxiety in patients with rosacea. Material and Methods- Seventy-three patients, aged 18 years or above, with a clinical diagnosis of rosacea were included in the study. All patients completed a Dermatology Life Quality Index (DLQI) questionnaire and a Hospital Anxiety and Depression Scale (HADS) quessionaire. Results: The mean DLQI score of patients was 7.98 ± 5.86 which signified a moderate impact on quality of life. The mean HADS-A (anxiety) score was 4.83 ± 4.42, while the mean HADS-D (depression) score was 5.22 ± 4.04. Thirteen (17.81%) patients had anxiety HADS-A (≥11 points) while 11 (15.07%) patients had depression HADS-D (≥11 points). Total DLQI score of patients with rosacea correlated positively with anxiety (r = 0.67, p value- <0.001) and depression (r = 0.49, p value- <0.001) Conclusion: Rosacea is a distressing disease which has a moderate impact on patient’s QOL. Dermatologists must always be vigilant of the psychosocial aspects of rosacea and should opt for the self-perception of rosacea by patients while prescribing a treatment regimen. Keywords: Rosacea, dermatology life quality index, DLQI, Hospital Anxiety and Depression Scale, HADS

2015 ◽  
Vol 20 (3) ◽  
pp. 211-215 ◽  
Author(s):  
Jennifer M. Salsberg ◽  
Miriam Weinstein ◽  
Neil Shear ◽  
Michelle Lee ◽  
Elena Pope

Background/Objectives: Cosmetic camouflage is known to improve quality of life in adults. Few data are available regarding cosmetic camouflage in children, and thus it is not often selected as a mode of treatment. We sought to determine whether cosmetic camouflage leads to improved quality of life of pediatric patients with visible dermatoses and their parent or primary caregiver. Methods: Patients aged 5 to 17 years with visible skin disease and their parent were assessed with the Children’s Dermatology Life Quality Index (CDLQI) and the Family Dermatology Life Quality Index (FDLQI) before and after consultation regarding cosmetic camouflage. Results: Twenty-two children with skin conditions were included in the study. The mean CDLQI decreased from 6.82 (SD = 1.28) to 3.05 (SD = 0.65; P = .0014), while the mean FDLQI decreased from 7.68 (SD = 1.15) to 4.68 (SD = 0.92; P = .0012). Conclusions: Our study highlighted improvement in quality of life in patients with skin disorders who were managed with cosmetic camouflage.


Author(s):  
Sangeeta Hatila ◽  
Aastha Dhingra Hasija ◽  
Vijay Choudhary

Background: Chronic diseases are known to have impact on quality of life of patients as of the acne. The DLQI (dermatology life quality index) is a scale to assess quality of life of the patients with skin disease. Objectives: The present study analyses the quality of life patients with acne attending OPD of skin department, SMS hospital. Methods: A questionnaire-based prospective study was conducted among 150 patients with acne referred from department of dermatology, SMS hospital. Results: The mean DLQL score was 7.28, the question about how embarrassed or self-conscious have you been because of skin had highest whereas the question about how much has your skin caused any sexual difficulties? had lowest scores. Conclusion: Acne has moderate effect of quality of life of the patients. There is need for psychological intervention to improve the quality of life of the patients. Keywords:  Acne, dermatology life quality index, quality of life.


2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Justyna Szczęch ◽  
Dominik Samotij ◽  
Kamila Jaworecka ◽  
Aleksandra Tobiasz ◽  
Adam Reich

Introduction. Morphea (or localized scleroderma) is an inflammatory, immune-mediated disease of unknown etiology. It is characterized by excessive collagen deposition that leads to hardening of the dermis, subcutaneous tissues, or both. Morphea is associated with cosmetic and functional impairment, which might affect the patients’ quality of life (QoL). Objective. The aim of the study was to evaluate QoL in patients suffering from morphea. Material and Methods. Sixty-five patients with morphea were recruited into this cross-sectional, prospective parallel study. QoL among adult patients was assessed with the Dermatology Life Quality Index (DLQI) and Euro-QoL-5D questionnaire; patients aged <17 years used the Children’s Dermatology Life Quality Index (CDLQI). The severity of morphea was assessed using the Localized Scleroderma Cutaneous Assessment Tool. The results of QoL and its association with disease severity were compared between patients with various morphea subtypes. Results. The mean DLQI scoring was 3.8±4.1 points and the CDLQI was 2.3±3.0. The mean value of Visual Analogue Scale thermometer (EQ VAS) was 66.9±17.5 points. The disease activity of morphea based on mLoSSI correlated significantly with QoL impairment according to the DLQI (R=0.41, p=0.001). No significant correlation was observed between morphea-induced damage and QoL (p=0.99). Conclusions. Evaluation of QoL in patients with morphea is still challenging due to lack of good assessment tools dedicated specifically for morphea patients. In general, QoL in morphea patients is significantly correlated with the disease activity, but not with disease-induced skin damage.


2005 ◽  
Vol 125 (4) ◽  
pp. 659-664 ◽  
Author(s):  
Yan Hongbo ◽  
Charles L. Thomas ◽  
Michael A. Harrison ◽  
M. Sam Salek ◽  
Andrew Y. Finlay

2012 ◽  
Vol 87 (5) ◽  
pp. 697-702 ◽  
Author(s):  
Magda Blessmann Weber ◽  
Daniel Lorenzini ◽  
Clarissa Prieto Herman Reinehr ◽  
Bárbara Lovato

BACKGROUND: Skin diseases cause negative impact on the emotional state, social relationships and daily activities, due to the stigma caused by the appearance of the lesions. OBJECTIVE: This study aimed to assess the quality of life of pediatric patients with skin diseases attending a dermatology service, compare the scores obtained among the dermatoses found in the sample and associate them to the variables, in addition to observing how the skin disease specifically affects quality of life. METHODS: Cross-sectional study, with patients between 5 and 16 years attending the Dermatology Service of the University of Health Sciences of Porto Alegre, Brazil, between July 2010 and February 2011. The data collection instruments were the Children's Dermatology Life Quality Index questionnaire and the AUEQI questionnaire. RESULTS: A total of 161 patients were interviewed, with mean age of 9,66 years. The main dermatoses were atopic dermatitis (29.8%), warts (13%) and molluscum contagiosum (7.5%). Chronic diseases (73.9%) were the most prevalent. The overall mean Children's Dermatology Life Quality Index score was 5.01 for chronic dermatoses and 2.07 for acute illnesses, indicating a compromised quality of life among chronically ill patients. The comparison between the scores obtained with the AUEQI scale and the Children's Dermatology Life Quality Index scores indicates that the overall quality of life is less affected than the specific quality of life related to the dermatosis. CONCLUSIONS: The data presented reinforce how important it is that the patients, their families and caregivers understand the symptoms, triggers and treatment of the skin disease in question. This information facilitates adherence to the treatment and justifies the conduct adopted by the dermatologist.


2018 ◽  
Vol 2 (5) ◽  
Author(s):  
Giselle Prado ◽  
Anna J Nichols ◽  
Mercedes Florez-White ◽  
Francisco Kerdel

Background: Psoriasis is a chronic remitting and relapsing skin disease. For many patients, improved quality of life (QoL) is as important as clinical improvement of lesions.Objective: To review reporting of Dermatology Life Quality Index (DLQI) in randomized controlled trials (RCTs) of biologics for adult patients with plaque psoriasis.Methods: A systematic review was conducted in 4 databases for RCTs that measured DLQI at baseline and endpoint. A data collection form was created for collecting study variables. Risk of bias was assessed using the Cochrane risk of bias tool.Results: Thirty-four RCTs enrolling 16,784 patients were included. Complete baseline and final mean DLQI data was retrieved for 24 studies (70.6%). The mean DLQI at baseline was reported in 79.4% of RCTs. The median at baseline was reported in 14.7% of RCTs. The mean DLQI at endpoint was reported in 23.5% of RCTs and the median DLQI at endpoint was reported in 5.9% of RCTs. The mean change in DLQI was reported in 64.7% of RCTs.Conclusions: DLQI was measured in most clinical trials assessing the efficacy of biologics for psoriasis. Studies did not adhere to uniform standards in publishing results, making analysis of the impact on DLQI challenging.Key Words: plaque psoriasis, quality of life, Dermatology Life Quality Index, Systematic Review, biologic therapy


2015 ◽  
Vol 19 (6) ◽  
pp. 546-554 ◽  
Author(s):  
K. Heelan ◽  
S. L. Hitzig ◽  
S. Knowles ◽  
A. M. Drucker ◽  
N. Mittmann ◽  
...  

Background: Little is known about quality of life and work productivity in autoimmune bullous dermatoses (AIBDs). Objective: To determine the impact of AIBDs on quality of life and work productivity. Methods: An observational cross-sectional study took place between February and May 2013 at an AIBD tertiary referral centre. Ninety-four patients were included. All participants completed the Dermatology Life Quality Index and the Work Productivity and Activity Impairment–Specific Health Problem questionnaires. Results: Responders to treatment had less impairment ( P < .001) than nonresponders. Patients with severe AIBD had significantly more impairment that those with mild ( P < .001) and moderate ( P = .002) AIBD. Greater impairment was associated with higher percentage of work missed. Those with a higher Dermatology Life Quality Index score had greater work impairment and overall activity impairment ( P = .041, P = .024). Nonresponders had increased impairment while working ( P < .001), overall work impairment ( P < .001), and activity impairment ( P < .001). Severely affected patients had worse impairment in all Work Productivity and Activity Impairment Questionnaire domains. Conclusions: AIBD has the potential to be a large burden on ability to work and quality of life. Larger studies are needed to clarify how these domains change over time and whether or not they improve with treatment.


Sign in / Sign up

Export Citation Format

Share Document